Zealand Pharma announces survodutide trial reducing visceral and liver fat
Results also showed 63% liver fat reduction and minimized lean mass loss, supporting metabolic health improvement.
See the latest news and media coverage for Zealand Pharma. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biotechnology company focused on metabolic health medicines
zealandpharma.comLast updated
In short: Zealand Pharma advanced its obesity drug pipeline, notably moving petrelintide to Phase 3, while launching a DKK 1.3 billion share buy-back program.
Results also showed 63% liver fat reduction and minimized lean mass loss, supporting metabolic health improvement.
The ZUPREME-1 trial showed double-digit weight loss and placebo-like tolerability at 42 weeks, supporting Phase 3 plans for second half of 2026.
The company repurchased 162,000 shares for DKK 51.9 million in week 22 of 2026.
The meeting elected Camilla Sylvest to the Board and authorized the chair for registration changes.
Zealand fell 23% - but partner still believes in weight loss hopeA quarter of the market value was lost on the day, when the weight loss hope survodutide from Zealand Pharma disappointed...
The Danish biotech stock Zealand Pharma is no longer as attractive. This is the message from the financial firm Berenberg, which has lowered its recommendation of the stock to...
Zealand Pharma downgraded at Wolfe on concerns over obesity drug tolerability...
At closing time Monday, the share price in the Danish biotech company Zealand Pharma fell by 22.7 percent in the wake of new data on the weight-loss drug survodutid. It writes...
Track Zealand Pharma and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Zealand Pharma and other trending companies.